Risk assessments for ovarian tumors are ever-evolving, as advances in diagnostic imaging and biomarker development pave the way. What are the current views on overian tumor risk assessment, and how should they be incorporated into clinical practice? Joining Dr. Matt Birnholz to address these questions is Dr. Fred Ueland, Professor of Obstetrics and Gynecology, and Director of Gynecologic Oncology at the University of Kentucky.
advertisement
Evolving Views on Ovarian Tumor Risk Assessments
Share
SaveShare this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Sponsored by
Overview
Risk assessments for ovarian tumors are ever-evolving, as advances in diagnostic imaging and biomarker development pave the way. What are the current views on overian tumor risk assessment, and how should they be incorporated into clinical practice? Joining Dr. Matt Birnholz to address these questions is Dr. Fred Ueland, Professor of Obstetrics and Gynecology, and Director of Gynecologic Oncology at the University of Kentucky.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?